HER2/EGFR-AKT Signaling Switches TGFβ from Inhibiting Cell Proliferation to Promoting Cell Migration in Breast Cancer.

TGFβ signaling inhibits cell proliferation to block cancer initiation, yet it also enhances metastasis to promote malignancy during breast cancer development. The mechanisms underlying these differential effects are still unclear. Here, we report that HER2/EGFR signaling switches TGFβ function in breast cancer cells from antiproliferation to cancer promotion. Inhibition of HER2/EGFR activity attenuated TGFβ-induced epithelial-mesenchymal transition and migration but enhanced the antiproliferative activity of TGFβ. Activation of HER2/EGFR induced phosphorylation of Smad3 at Ser208 of the linker region through AKT, which promoted the nuclear accumulation of Smad3 and subsequent expression of the genes related to EMT and cell migration. In contrast, HER2/EGFR signaling had no effects on the nuclear localization of Smad2. Knockdown of Smad3, but not Smad2, blocked TGFβ-induced breast cancer cell migration. We observed a positive correlation between the nuclear localization of Smad3 and HER2 activation in advanced human breast cancers. Our results demonstrate a key role for HER2/EGFR in differential regulation of Smad3 activity to shift TGFβ function from antitumorigenic to protumorigenic during breast cancer development.Significance: TGFβ signaling can shift from inhibiting to promoting breast cancer development via HER2/EGFR AKT-mediated phosphorylation of Smad3 at S208, enhancing its nuclear accumulation and upregulation of EMT-related genes.Graphical Abstract: http://cancerres.aacrjournals.org/content/canres/78/21/6073/F1.large.jpg Cancer Res; 78(21); 6073-85. ©2018 AACR.

[1]  Jing Huang,et al.  Direct Regulation of Alternative Splicing by SMAD3 through PCBP1 Is Essential to the Tumor-Promoting Role of TGF-β. , 2016, Molecular cell.

[2]  A. Hata,et al.  TGF-β Signaling from Receptors to Smads. , 2016, Cold Spring Harbor perspectives in biology.

[3]  C. Arteaga,et al.  The PI3K/AKT Pathway as a Target for Cancer Treatment. , 2016, Annual review of medicine.

[4]  S. Park,et al.  Kaempferol Suppresses Transforming Growth Factor-β1–Induced Epithelial-to-Mesenchymal Transition and Migration of A549 Lung Cancer Cells by Inhibiting Akt1-Mediated Phosphorylation of Smad3 at Threonine-179 , 2015, Neoplasia.

[5]  Jun Yao,et al.  14-3-3ζ turns TGF-β's function from tumor suppressor to metastasis promoter in breast cancer by contextual changes of Smad partners from p53 to Gli2. , 2015, Cancer cell.

[6]  A. Puisieux,et al.  Oncogenic roles of EMT-inducing transcription factors , 2014, Nature Cell Biology.

[7]  J. Engelman,et al.  ERBB receptors: from oncogene discovery to basic science to mechanism-based cancer therapeutics. , 2014, Cancer cell.

[8]  陳韻如,et al.  Lapatinib-Mediated Cyclooxygenase-2 Expression via Epidermal Growth Factor Receptor/HuR Interaction Enhances the Aggressiveness of Triple-Negative Breast Cancer Cells , 2013 .

[9]  K. Matsuzaki.  Smad phospho-isoforms direct context-dependent TGF-β signaling. , 2013, Cytokine & growth factor reviews.

[10]  T. Horibe,et al.  HER2-Targeted Hybrid Peptide That Blocks HER2 Tyrosine Kinase Disintegrates Cancer Cell Membrane and Inhibits Tumor Growth In Vivo , 2013, Molecular Cancer Therapeutics.

[11]  J. Massagué.  TGFβ signalling in context , 2012, Nature Reviews Molecular Cell Biology.

[12]  B. Hemmings,et al.  PI3K-PKB/Akt pathway. , 2012, Cold Spring Harbor perspectives in biology.

[13]  C. Heldin,et al.  Regulation of EMT by TGFβ in cancer , 2012, FEBS letters.

[14]  J. Jeruss,et al.  Phospho-specific Smad3 signaling , 2012, Cell cycle.

[15]  Y. Inoue,et al.  The roles of TGF-β signaling in carcinogenesis and breast cancer metastasis , 2012, Breast Cancer.

[16]  C. Arteaga,et al.  When Tumor Suppressor TGFβ Meets the HER2 (ERBB2) Oncogene , 2011, Journal of Mammary Gland Biology and Neoplasia.

[17]  J. Alcorn,et al.  c-Jun N-terminal kinase 1 promotes transforming growth factor-β1-induced epithelial-to-mesenchymal transition via control of linker phosphorylation and transcriptional activity of Smad3. , 2011, American journal of respiratory cell and molecular biology.

[18]  S. Wang,et al.  The Functional Crosstalk between HER2 Tyrosine Kinase and TGF-β Signaling in Breast Cancer Malignancy , 2011, Journal of signal transduction.

[19]  S. Cole,et al.  Intrinsic Breast Tumor Subtypes, Race, and Long-Term Survival in the Carolina Breast Cancer Study , 2010, Clinical Cancer Research.

[20]  J. Massagué,et al.  HER2 silences tumor suppression in breast cancer cells by switching expression of C/EBPß isoforms. , 2010, Cancer research.

[21]  A. Li,et al.  UC Office of the President Recent Work Title Context-dependent bidirectional regulation of the mutS homolog 2 by transforming growth factor β contributes to chemoresistance in breast cancer cells , 2010 .

[22]  Kohei Miyazono,et al.  TGFβ signalling: a complex web in cancer progression , 2010, Nature Reviews Cancer.

[23]  Sho Fujisawa,et al.  Nuclear CDKs Drive Smad Transcriptional Activation and Turnover in BMP and TGF-β Pathways , 2009, Cell.

[24]  I. Matsuura,et al.  Transforming Growth Factor-β-inducible Phosphorylation of Smad3* , 2009, Journal of Biological Chemistry.

[25]  Xin-Hua Feng,et al.  Nuclear export of Smad2 and Smad3 by RanBP3 facilitates termination of TGF-beta signaling. , 2009, Developmental cell.

[26]  A. Pozzi,et al.  Transforming growth factor beta induces clustering of HER2 and integrins by activating Src-focal adhesion kinase and receptor association to the cytoskeleton. , 2009, Cancer research.

[27]  Ye Guang Chen,et al.  Specific Activation of Mitogen-activated Protein Kinase by Transforming Growth Factor-␤ Receptors in Lipid Rafts Is Required for Epithelial Cell Plasticity Transforming Growth Factor (tgf)-␤ Regulates a Spectrum of Cellular Events, including Cell Proliferation, Differentiation, and Migration. in Add , 2008 .

[28]  Xin-Hua Feng,et al.  Phospho-control of TGF-β superfamily signaling , 2009, Cell Research.

[29]  Ying E Zhang,et al.  Non-Smad pathways in TGF-β signaling , 2009, Cell Research.

[30]  C. Hill.  Nucleocytoplasmic shuttling of Smad proteins , 2009, Cell Research.

[31]  J. Massagué,et al.  TGFβ in Cancer , 2008, Cell.

[32]  C. Heldin.  TGF-beta signaling from receptors to Smads , 2008 .

[33]  Lewis C. Cantley,et al.  AKT/PKB Signaling: Navigating Downstream , 2007, Cell.

[34]  Ching-Yu Chen,et al.  Overcoming Trastuzumab Resistance in HER2-Overexpressing Breast Cancer Cells by Using a Novel Celecoxib-Derived Phosphoinositide-Dependent Kinase-1 Inhibitor , 2006, Molecular Pharmacology.

[35]  Frederick Y. Wu,et al.  HER2/Neu (ErbB2) signaling to Rac1-Pak1 is temporally and spatially modulated by transforming growth factor beta. , 2006, Cancer research.

[36]  Ron Bose,et al.  Phosphoproteomic analysis of Her2/neu signaling and inhibition. , 2006, Proceedings of the National Academy of Sciences of the United States of America.

[37]  K. Flanders,et al.  Smad3 is key to TGF-beta-mediated epithelial-to-mesenchymal transition, fibrosis, tumor suppression and metastasis. , 2006, Cytokine & growth factor reviews.

[38]  R. Derynck,et al.  SPECIFICITY AND VERSATILITY IN TGF-β SIGNALING THROUGH SMADS , 2005 .

[39]  Roman Rouzier,et al.  Breast Cancer Molecular Subtypes Respond Differently to Preoperative Chemotherapy , 2005, Clinical Cancer Research.

[40]  Anita B. Roberts,et al.  Role of Rho/ROCK and p38 MAP Kinase Pathways in Transforming Growth Factor-β-mediated Smad-dependent Growth Inhibition of Human Breast Carcinoma Cells in Vivo* , 2004, Journal of Biological Chemistry.

[41]  R. Derynck,et al.  Specificity and versatility in tgf-beta signaling through Smads. , 2005, Annual review of cell and developmental biology.

[42]  H. Matsui,et al.  TGF-β and HGF transmit the signals through JNK-dependent Smad2/3 phosphorylation at the linker regions , 2004, Oncogene.

[43]  C. Arteaga,et al.  Overexpression of HER2 (erbB2) in Human Breast Epithelial Cells Unmasks Transforming Growth Factor β-induced Cell Motility* , 2004, Journal of Biological Chemistry.

[44]  K. Luo,et al.  Akt interacts directly with Smad3 to regulate the sensitivity to TGF-β-induced apoptosis , 2004, Nature Cell Biology.

[45]  Joshua LaBaer,et al.  Cooperation of the ErbB2 receptor and transforming growth factor beta in induction of migration and invasion in mammary epithelial cells. , 2004, Proceedings of the National Academy of Sciences of the United States of America.

[46]  Huali,et al.  Downregulation of wild-type p53 protein by HER-2／neu mediated PI3K pathway activation in human breast cancer cells： its effect on cell proliferation and implication for therapy , 2004 .

[47]  S. Michnick,et al.  PKB/Akt modulates TGF-beta signalling through a direct interaction with Smad3. , 2004, Nature cell biology.

[48]  Dana M. Brantley-Sieders,et al.  Increased Malignancy of Neu-Induced Mammary Tumors Overexpressing Active Transforming Growth Factor β1 , 2003, Molecular and Cellular Biology.

[49]  M. Reiss,et al.  Insulin-like Growth Factor-I Inhibits Transcriptional Responses of Transforming Growth Factor-β by Phosphatidylinositol 3-Kinase/Akt-dependent Suppression of the Activation of Smad3 but Not Smad2* , 2003, Journal of Biological Chemistry.

[50]  R. Cardiff,et al.  Transforming growth factor beta signaling impairs Neu-induced mammary tumorigenesis while promoting pulmonary metastasis. , 2003, Proceedings of the National Academy of Sciences of the United States of America.

[51]  Denis Vivien,et al.  Direct binding of Smad3 and Smad4 to critical TGFβ‐inducible elements in the promoter of human plasminogen activator inhibitor‐type 1 gene , 1998, The EMBO journal.

[52]  Minoru Watanabe,et al.  Smad4 and FAST-1 in the assembly of activin-responsive factor , 1997, Nature.